TuHURA Biosciences (NASDAQ:HURA) Upgraded at Brookline Capital Management
Brookline Capital Management upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports. Brookline Capital Management also issued estimates for TuHURA Biosciences’ Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at […]
Brookline Capital Management upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports. Brookline Capital Management also issued estimates for TuHURA Biosciences’ Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at […]
-logo-1200x675.png?v=20220818172429&w=240&h=240&zc=2){kind=logo}
